Patents Assigned to Jazz Pharmaceuticals Ireland Limited
  • Patent number: 11986446
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Grant
    Filed: December 27, 2021
    Date of Patent: May 21, 2024
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Mark Eller
  • Publication number: 20240156759
    Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.
    Type: Application
    Filed: June 30, 2023
    Publication date: May 16, 2024
    Applicant: Jazz Pharmaceuticals Ireland Limited
    Inventors: Clark P. Allphin, Michael DesJardin
  • Patent number: 11980636
    Abstract: The invention relates to compositions and methods for treating patients with hematological proliferative disorders with CPX-351, a liposomal composition of daunorubicin and cytarabine, and venetoclax.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: May 14, 2024
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Stefan Faderl
  • Patent number: 11858930
    Abstract: The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: January 2, 2024
    Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITED
    Inventors: Andrew Belfield, Clifford David Jones, Jean-François Margathe, Chiara Colletto
  • Publication number: 20230390228
    Abstract: Provided herein are methods of treating fibromyalgia, post-traumatic stress disorder, irritable bowel syndrome, and irritable bowel disease in a patient with a slow wave sleep deficit by administering oxybate or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 18, 2021
    Publication date: December 7, 2023
    Applicant: Jazz Pharmaceuticals Ireland Limited
    Inventors: Franck SKOBIERANDA, Mark Toddman KIRBY
  • Publication number: 20230339910
    Abstract: Provided herein are compounds identified as inhibitors of KRAS protein activity that can be used to treat various diseases and disorders, such as cancer.
    Type: Application
    Filed: January 29, 2021
    Publication date: October 26, 2023
    Applicant: Jazz Pharmaceuticals Ireland Limited
    Inventors: Andrew BELFIELD, Nicolas Emmanuel Stephane GUISOT, Clifford David JONES, Chiara COLLETTO
  • Patent number: 11571440
    Abstract: The present disclosure provides method of preventing, lessening the effects, or treating cytokine release syndrome (CRS) or related disorders, and/or neurotoxicity associated with immunotherapy comprising administering defibrotide. The defibrotide can be administered after the immunotherapy begins or be administered prophylactically before immunotherapy begins or before the patient develops CRS and/or neurotoxicity.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: February 7, 2023
    Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITED
    Inventors: Sarah McMahon, Yasuhiro Oki
  • Patent number: 11554102
    Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: January 17, 2023
    Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITED
    Inventors: Clark P. Allphin, Michael DesJardin
  • Patent number: 11426373
    Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: August 30, 2022
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventors: Clark P. Allphin, Gunjan Junnarkar, Roman Skowronski, Cuiping Chen, Katayoun Zomorodi, Mark Eller
  • Patent number: 11413264
    Abstract: The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: August 16, 2022
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Fionn Hurley
  • Patent number: 11400052
    Abstract: The invention relates to modified release oral formulations of therapeutic agents, including gamma hydroxybutyrate (GHB), paracetamol, codeine or oxycodone, which are resistant to alcohol induced dose dumping. Provided are formulations that have improved resistance to rapid release of the active ingredient in the presence of increasing amounts of alcohol. Also provided are formulations that can reduce or prevent the release of the active ingredient following exposure to alcohol-containing media. The invention also relates to methods of making the formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: August 2, 2022
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventors: Edwin Walsh, Clark Patrick Allphin
  • Publication number: 20220193015
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Application
    Filed: December 27, 2021
    Publication date: June 23, 2022
    Applicant: Jazz Pharmaceuticals Ireland Limited
    Inventor: Mark ELLER
  • Patent number: 11364215
    Abstract: The present application relates to GHB formulations and methods for manufacturing the same.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: June 21, 2022
    Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITED
    Inventors: Clark Allphin, Scott Bura
  • Patent number: 11253494
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: February 22, 2022
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Mark Eller
  • Publication number: 20220000815
    Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.
    Type: Application
    Filed: September 20, 2021
    Publication date: January 6, 2022
    Applicant: Jazz Pharmaceuticals Ireland Limited
    Inventors: Clark P. Allphin, Michael DesJardin
  • Publication number: 20210361601
    Abstract: Provided herein are methods of administering GHB formulations for the treatment of narcolepsy and other conditions.
    Type: Application
    Filed: August 6, 2021
    Publication date: November 25, 2021
    Applicant: JAZZ PHARMACEUTICALS IRELAND LIMITED
    Inventor: Franck SKOBIERANDA
  • Patent number: 11160779
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: November 2, 2021
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Katayoun Zomorodi
  • Patent number: 11147782
    Abstract: The present application relates to GHB formulations and methods for manufacturing the same.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: October 19, 2021
    Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITED
    Inventors: Clark Allphin, Scott Bura
  • Patent number: 11149000
    Abstract: The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: October 19, 2021
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventors: Fionn Hurley, Lawrence Patrick Carter
  • Patent number: RE49361
    Abstract: This invention relates to novel compounds. The compounds of the invention are kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Raf kinases, e.g., B-Raf and C-Raf. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Raf kinases, for example, cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: January 10, 2023
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventors: Matilda Bingham, Richard Testar, Camille Gignoux